期刊
EXPERT OPINION ON THERAPEUTIC PATENTS
卷 29, 期 10, 页码 761-767出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/13543776.2019.1671353
关键词
Age-related macular degeneration; macular edema; VEGF; ranibizumab; bevacizumab; aflibercept; pegaptanib; carbonic anhydrase; sulfonamide
Introduction: Macular degeneration (MD) and macular edema (ME) are ophthalmologic diseases affecting an increasing number of the aging population. Until recently, there were few therapeutic options for both conditions but the last two decades saw important advances. Areas covered: This review summarizes the agents used for the treatment of age-related MD (AMD), which include verteporfin, for photodynamic therapy, and anti-VEGF agents, the aptamer pegaptanib, the monoclonal antibodies (MAbs) ranibizumab (Lucentis (R)) and bevacizumab (Avastin (R)) and the fusion protein aflibercept (Eylea (R)). All these drugs are effective only for the wet form of AMD, whereas for the dry form there is no treatment available. ME is, on the other hand, treated with nonsteroidal anti-inflammatory drugs and carbonic anhydrase (CA) inhibitors. Recently, MAbs such as ranibizumab and bevacizumab were also shown to be effective for the management of the cystoid and diabetic ME. Expert opinion: There are important advances made in the field in the last years but longer-acting anti-VEGF agents or drugs with less ocular side effects are needed. Many such agents are in clinical development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据